News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) Announces Phase 1 Data For Investigational Therapy, GS-6615, In Patients With Long QT-3 Syndrome


5/12/2014 9:19:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1 clinical trial (GS-US-279-0110) of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats). Results from this study (Abstract #AB34-05) will be presented today in San Francisco at the annual meeting of the Heart Rhythm Society.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES